Algorithms for the pharmacotherapy of anxiety disorders in patients with chemical abuse and dependence

Psychiatric Annals

Volumn 29, Issue 5, 1999, Pages 285-301

  Osser, David N ^a,b,d   Renner Jr , John A ^c   Bayog, Rogelio ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Taunton State Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033418249     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-19990501-10     Document Type: Article

References (95)

1. Kesslet RC, Nelson CB, McGonagle KA, Edlund MG, Frank RG, Leaf PJ. The epidemiology of co-occurring mental disorders and substance use disorders in the National Comorbidity Survey: implications for prevention and service utilization. Am J Orthopsychiatry. 1996;66:17-31.
2. Sussman N. Interactive treatment algorithms for anxiety disorders. Primary Psychiatry. 1997;4:16-80.
3. Stein DJ, Jobson KO. Pharmacotherapy algorithms for anxiety disorders. Psychiatric Annals. 1996;26:190-232.
4. Jobson KO, Potter WZ. International psychopharmacology algorithm project report. Psychopharmacol Bull. 1995;31:483-507.
5. Longo LP. Non-benzodiazepine pharmacotherapy of anxiety and panic in substance abusing patients. Psychiatric Annals. 1998;28:142-153.
6. Fawcett J. Science, balance, and passion. Psychiatric Annals. 1998;28:116-117.
7. American Psychological Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
8. Kranzler HR, Burleson JA, Del Boca FK, et al. Buspirone treatment of anxious alcoholics: a placebo controlled trial. Arch Gen Psychiatry. 1994;51:720-731.
9. Mason BJ, Kocsis JH, Ritvo EC, Cutler RB. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence, stratified on the presence or absence of major depression. JAMA. 1996;275:761-767.
10. Osser DN. How is naltrexone used in the treatment of alcoholism? The Harvard Mental Health Letter. 1998;15:8.
11. Perez-Cruet JF, Iricanin T. Immediate naltrexone decreases in alcohol intake urges as predictor of a good outcome (NR 387). American Psychiatric Association Annual Meeting; San Diego, California; 1997.
12. Volpicelli JR, Rhines KC, Thines JS, Volpicelli LA, Altennan AI, O'Brien CP. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry. 1997;54:737-742.
13. O'Malley SS. Integration of opioid antagonists and psychosocial therapy in the treatment of narcotic and alcohol dependence. J Clin Psychiatry. 1995;56:30-38.
14. Goldenberg IM, White K, Yonkers K, et al. The infrequency of "pure culture" diagnoses among the anxiety disorders. J Clin Psychiatry. 1996;57:528-533.
15. Brawman-Mintzer O, Lydiard RB. Psychopharmacology of anxiety disorders: treatment resistance. Psychiatr Clin North Am. 1996;3:66-67.
16. Milrod B, Busch F, Cooper AM, Shapiro T. Manual of Panic-Focused Psychodynamic Psychotherapy. Washington, DC: American Psychiatric Press; 1997:128.
17. Rosenbaum JF, Pollack MH, Fredman SJ. The pharmacotherapy of panic disorder. In: Rosenbaum JF, Pollack MH, eds. Panic Disorder and Its Treatment. New York: Marcel Dekker; 1998:153-180.
18. American Psychiatric Association. Practice guidelines for the treatment of patients with panic disorder. Am J Psychiatry. 1998;155:23.
19. Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacol Rev. 1992;44:151-347.
20. Fraser AD. Use and abuse of benzodiazepines. Ther Drug Monit. 1998;20:481-489.
21. DuPont RL. Anxiety and addiction: a clinical perspective on comorbidity. Bull Menninger Clin. 1995;59:A53-A72.
22. Ciraulo DA, Barnhill JG, Ciraulo AM, et al. Alterations in pharmacodynamics of anxiolytics in abstinent alcoholic men: subjective responses, abuse liability, and electroencephalographic effects of alprazolam, diazepam, and buspirone. J Clin Pharmacol. 1997;37:64-73.
23. Humble M, Wistedt B. Serotonin, panic disorder, and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders. Int Clin Psychopharmacol. 1992;6:21-39.
24. Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry. 1998;55:1010-1016.
25. Schneier FR, Liebowitz MR, Davies SO, et al. Fluoxetine in panic disorder. J Clin Psychopharmacol. 1990;10:119-121.
26. Pollack MH, Worthington JJ, Otto MW, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull. 1996;32:667-670.
27. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998;59:502-508.
28. Mavissakalian M, Perel J, Bowler K, Dealy R. Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am J Psychiatry. 1987;144:785-787.
29. Woods SW, Nagy LM, Koleszar AS, Krystal JH, Heninger GR, Charney DS. Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. J Clin Psychopharmacol. 1992;12:32-38.
30. Woodman CL, Noyes R Jr. Panic disorder: treatment with valproate. J Clin Psychiatry. 1994;55:134-136.
31. Crockatt JO, Greiner M, Clift LL, Pande AC. Treatment of panic disorder with gabapentin (Poster 154). New Clinical Drug Evaluation Unit Program; Boca Raton, Florida; National Institute of Mental Health; 1998.
32. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
33. Fones CSL, Manfro GG, Pollack MH. Social phobia: an update. Harv Rev Psychiatry. 1998;5:247-259.
34. Schuckit MA, Hellelbrock V. Alcohol dependence and anxiety disorders: what is the relationship? Am J Psychiatry. 1994;151:1723-1734.
35. Lockwood AH. Medical problems of musicians. N Engl J Med. 1989;320:221-227.
36. Bouwer C, Stein DJ. Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia. J Affect Disord. 1998;49:79-82.
37. Van Ameringen MA, Mancini CL, Oakman JM. Nefazodone in social phobia. J Clin Psychiatry. 1999;60: 96-100.
38. Worthington JJ III, Zucker BG, Fones CSL, Otto MW, Pollack MH. Nefazodone for social phobia: a clinical case series. Depress Anxiety. 1998;8:131-133.
39. Davidson JRT. Pharmacotherapy of social anxiety disorder. J Clin Psychiatry. 1998;59(suppl 17):52.
40. Ware MW, Emmanuel NP, Johnson MR, Brawman-Mintzer O, Kapp R, Lydiard RB. Self-reported sexual dysfunctions in anxiety disorder patients (NR676). American Psychiatric Association Annual Meeting; New York, New York; 1996.
41. Schneier FR, Goetz D, Campeas R, Fallon B, Marshall R, Liebowitz MR. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry. 1998;172:70-77.
42. Osser DN, Patterson RD. Algorithms for the pharmacotherapy of depression: part one and part two. Directions in Psychiatry. 1998;18:303-336.
43. Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia. Arch Gen Psychiatry. 1998;55:1133-1141.
44. van Vliet IM, den Boer JA, Westenberg HGM, Ho Pian KL. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry. 1997;58:164-168.
45. Conner KM, Davidson JRT, Potts NLS, et al. Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol. 1998;18:373-378.
46. Marshall JR. The diagnosis and treatment of social phobia and alcohol abuse. Bull Menninger Clin. 1994;58:A58-A66.
47. Pande AC, Davidson JRT, Greist MH, Jefferson JW, Weisler R, Sutherland S. A placebo-controlled study of gabapentin in social phobia. American College of Neuropsychopharmacology Annual Meeting; San Juan, Puerto Rico; 1997.
48. Shear MK, Beidel DC. Psychotherapy in the overall management strategy for social anxiety disorder. J Clin Psychiatry. 1998;59(suppl 17):39-44.
49. DeBell C, Jones RD. As good as it seems? a review of EMDR experimental research. Professional Psychology: Research and Practice. 1997;28:153-163.
50. Ross RJ, Ball WA, Sullivan KA, Caroff SN. Sleep disturbance as the hallmark of posttraumatic stress disorder. Am J Psychiatry. 1989;146:697-707.
51. Kushida CA, Guilleminault C, Dement WC, Simon RD Jr, Ball EM. Diagnostic and treatment strategies for the obstructive sleep apnea syndrome. Journal of Clinical Outcomes Management. 1998;5:49-65.
52. Kupfer DJ, Reynolds CF III. Management of insomnia. N Engl J Med. 1997;336:341-345.
53. Rascati K. Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications. Clin Ther. 1995;17:786-790.
54. Friedman MJ. Current and future drug treatment for posttraumatic stress disorder patients. Psychiatric Annals. 1998;28:461-468.
55. Hertzberg MA, Feldman MD, Beckham JC, Davidson JRT. Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. J Clin Psychopharmacol. 1996;16:294-298.
56. Clark R, Canive J, Brugger R, Vosburgh T, Tuason V. Cyproheptadine in the treatment of nightmares with posttraumatic stress disorder (Poster 158). New Clinical Drug Evaluation Unit Program, 38th Annual Meeting; Boca Raton, Florida; National Institutes of Mental Health; 1998.
57. Chilcoat HD, Breslau N. Posttraumatic stress disorder and drug disorders. Arch Gen Psychiatry. 1998;55:913-917.
58. Marshall RD, Schneier FR, Fallon BA, et al. An open trial of paroxetine in patients with posttraumatic stress disorder. Int Clin Psychopharmacol. 1998;18:10-18.
59. Connor KM, Davidson JRT. The role of serotonin in posttraumatic stress disorder: neurobiology and pharmacotherapy. CNS Spectrums. 1998;3:43-51.
60. Davidson JRT, Weisler RH, Malik ML, Connor KM. Treatment of posttraumatic stress disorder with nefazodone. Int Clin Psychopharmacol. 1998;13:111-113.
61. Hertzberg MA, Feldman ME, Beckham JC, Moore SD, Davidson JRT. Open trial of nefazodone for combat-related posttraumatic stress disorder. J Clin Psychiatry. 1998;59:460-464.
62. Cornelius JR, Salloum IM, Ehler JG, et al. Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1997;54:700-705.
63. 62a. Brady KT, Sonne SC, Roberts JM. Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. J Clin Psychiatry. 1995;56:502-505.
64. Nierenberg AA, Adler LA, Peselow E, Zornberg G, Rosenthal M. Trazodone for antidepressant-associated insomnia. Am J Psychiatry. 1994;151:1069-1072.
65. David D, Kutcher GS, Jackson EI, Mellman TA. Psychotic symptoms in combat-related posttraumatic stress disorder. J Clin Psychiatry. 1999;60:29-32.
66. Hammer MB, Ulmer H, Horne DF, Frueh C, Twomey TJ, Chobot K. Psychotic features and symptom severity in PTSD (NR 611). American Psychiatric Association Annual Meeting; Toronto, Ontario, Canada; 1998.
67. Hammer MB, Ulmer H, Huber MG, Measom MO. Risperidone treatment of psychotic features in PTSD (NR 610). American Psychiatric Association Annual Meeting; Toronto, Ontario, Canada; 1998.
68. Penava SJ, Otto MW, Pollack MH, Rosenbaum JF. Current status of pharmacotherapy for PTSD: an effect size analysis of controlled studies. Depress Anxiety. 1997;4:240-242.
69. Fawcett J, Barkin RL. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry. 1998;59: 123-127.
70. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol. 1994;14:419-423.
71. Wheatley DP, van Moffaert M, Timmerman L, Kremer CME, MFS G. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry. 1998;59:306-312.
72. Clerc GE, Ruimy P, Verdeau-Pailles J, VFIS G. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol. 1994;9:139-143.
73. Connor KM, Davidson JRT, Weisler RH. A pilot study of mirtazapine in posttraumatic stress disorder (Poster III-98). 37th Annual Meeting of the American College of Neuropsychopharmacology; Las Croabas, Puerto Rico; 1998.
74. Canive JM, Clark RD, Calais LA, Qualls C, Tuason VB. Bupropion treatment in veterans with posttraumatic stress disorder: an open study. J Clin Psychopharmacol. 1998;18:379-383.
75. Fesler FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry. 1991;52:361-364.
76. Goodman WK, Ward HE, Murphy TK. Biologic approaches to treatment-refractory obsessive-compulsive disorder. Psychiatric Annals. 1998;28:641-649.
77. Greist JH, Jefferson JW. Pharmacotherapy for obsessive-compulsive disorder. Br J Psychiatry. 1998;173:64-70.
78. March JS, Francis A, Carpenter D, Kahn DA. The expert consensus guidelines series: treatment of obsessive-compulsive disorder. J Clin Psychiatry. 1997;58(suppl 4):1-72.
79. Montgomery S. Citalopram treatment of obsessive-compulsive disorder: results from a double-blind, placebo-controlled trial (Poster III-102). 37th Annual Meeting of the American College of Neuropsychopharmacology; Las Croabas, Puerto Rico; 1998.
80. Abramowitz JS. Effectiveness of psychological and pharmacological treatment for obsessive-compulsive disorder. Journal of Clinical and Consulting Psychology. 1997;65:44-52.
81. Oesterheld JR, Osser DN. Drug interactions in augmentation strategies for pharmacotherapy of obsessive-compulsive disorder. Journal of Practical Psychiatry and Behavioral Health. 1999. In press.
82. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. revised. Washington, DC: American Psychiatric Association; 1987.
83. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993;50:884-895.
84. Entsush R, Derivan AT, Haskins T, Rudolph RL, Aguiar L. Double-blind, placebo-controlled study of once-daily venlafaxine extended release and buspirone in outpatients with GAD (NR 644). American Psychiatric Association Annual Meeting; Toronto, Ontario, Canada; 1998.
85. Aguiar AM, Haskins T, Rudolf RL, Pallay A, Derivan AT. Double-blind, placebo-controlled study of once-daily venlafaxine extended release in outpatients with GAD (NP 643). American Psychiatric Association Annual Meeting; Toronto, Ontario, Canada; 1998.
86. Allgulander C, Cloninger CR, Przybeck TR, Brandt L. Changes on the temperament and character inventory after paroxetine treatment in volunteers with generalized anxiety disorder. Psychopharmacol Bull. 1998;34:165-166.
87. Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the national comorbidity survey. Arch Gen Psychiatry. 1994;51:355-354.
88. Brawman-Mintzer O, Lydiard RB, Emmanuel N, et al. Psychiatric comorbidity in patients with generalized anxiety disorder. Am J Psychiatry. 1993;150:1216-1218.
89. Thompson PM. Generalized anxiety disorder treatment algorithm. Psychiatric Annals. 1996;26:227-232.
90. Tollefson GD, Montague-Clouse J, Tollefson SL. Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J Clin Psychopharmacol. 1992;12: 19-26.
91. Apter JT, Allen LA. Buspirone: future directions. J Clin Psychopharmacol 1999;19:86-93.
92. van Laar MW, Volkerts ER, van Willigenburg APP. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients. J Clin Psychopharmacol. 1992;12:86-95.
93. Smiley A, Moskowitz H. Effects of long term administration of buspirone and diazepam on driver steering control. Am J Med. 1986;80:22-29.
94. Delle Chiaie R, Pancheri P, Casacchia M, Stratta P, Kotzalidis GD, Zibellini M. Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. J Clin Psychopharmacol. 1995;15:12-19.
95. DeMartinis NA, Rickels K, Mandos L, Rynn M, Schweizer E. Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder (Poster II-76). 37th Annual Meeting of the American College of Neuropsychopharmacology; Las Croabas, Puerto Rico; 1998.